InspireMD Q1 revenue up 4.7% to $1.24M; net loss $4.3M; completed $42.2M private placement

InspireMD, Inc.

2024-Q1 EPS reported -$0.53 revenue$1,239,000

Q1 2023 revenue $1.239M (+4.7% YoY); CGuard EPS revenue $1.239M (+6.7% YoY); net loss $4.256M ($0.53/sh).
Cash & equivalents $12.9M as of March 31, 2023; subsequent to quarter, completed $42.2M upfront private placement for up to $113.6M.
CE Mark reinstated under MDD in mid-March; shipments resumed; working through backlog; awaiting MDR recertification.
US IDE trial enrollment on track to complete by end of Q2 2023; FDA approved CGuard Prime delivery system for trial.
Hired Shane Gleason as GM of North America and VP Global Marketing; promoted Andrea Tommasoli to COO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

InspireMD, Inc. reported first quarter ended March 31, 2023 results: revenue $1,239,000.

Period: first quarter ended March 31, 2023
Revenue: $1,239,000
Result: reported results

Exact text from the filing

For the three months ended March 31, 2023, revenue increased by $56,000, or 4.7%, to $1,239,000, from $1,183,000 during the three months ended March 31, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

InspireMD, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-017646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.